Wednesday
11.13.2019
8:45 PM
Login form
Search
Calendar
Entries archive

My site

Main » 2016 » December » 19

SAINT-PREX, Switzerland - Monday, December 19th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Ferring Pharmaceuticals and IMAB today announced that they have signed a licensing agreement which grants IMAB exclusive rights to olamkicept (pINN) in Asia.

Olamkicept is a new recombinant protein inhibitor of the interleukin-6 pathway. Interleukin-6 is associated with numerous inflammatory conditions such as inflammatory bowel diseases (IBD) and rheumatoid arthritis.

The agreement provides IMAB with a Phase 2 ready asset with differentiated product profile. Under the terms of the arrangement, IMAB will fund further product development in exchange for an exclusive license in Asia with an option for worldwide use, with the goal of realizing the potential of olamkicept as a biomarker-guided and differentiated interleukin-6 blocker to treat autoimmune disease.

“We are very pleased to acquire the opportunity to further advance olamkicept and build on Ferring’ ... Read more »

Views: 103 | Added by: africa-live | Date: 12.19.2016 | Comments (0)